10-Q Filing

BIO-TECHNE CORP CIK: 842023 Q2 2024

Filing Information

Form Type	10-Q
Accession Number	`0001558370-24-000862`
Period End Date	20231231
Filing Date	20240207
Fiscal Year	2024
Fiscal Period	Q2
XBRL Instance	tmb-20231231x10q_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 83 Income Statement 90 Cash Flow Statement 85

Balance Sheet 83 line items

Line Item	Tag	Value	Unit	Period
Accounts receivable, allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$4.74M	USD	Point-in-time
Accounts receivable, allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$3.50M	USD	Point-in-time
Undesignated capital stock, no par (in dollars per share)	`UndesignatedCapitalStockNoParValue`	-	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$180.57M	USD	Point-in-time
Undesignated capital stock, no par (in dollars per share)	`UndesignatedCapitalStockNoParValue`	-	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$130.13M	USD	Point-in-time
Undesignated capital stock, shares authorized (in shares)	`UndesignatedCapitalStockSharesAuthorized`	5.00M	shares	Point-in-time
Short-term available-for-sale investments	`ShortTermInvestments`	$5.52M	USD	Point-in-time
Undesignated capital stock, shares authorized (in shares)	`UndesignatedCapitalStockSharesAuthorized`	5.00M	shares	Point-in-time
Short-term available-for-sale investments	`ShortTermInvestments`	$23.74M	USD	Point-in-time
Accounts receivable, less allowance for doubtful accounts of $3,502 and $4,738, respectively	`AccountsReceivableNetCurrent`	$218.47M	USD	Point-in-time
Undesignated capital stock, shares issued (in shares)	`UndesignatedCapitalStockSharesIssued`	0.00	shares	Point-in-time
Undesignated capital stock, shares issued (in shares)	`UndesignatedCapitalStockSharesIssued`	0.00	shares	Point-in-time
Accounts receivable, less allowance for doubtful accounts of $3,502 and $4,738, respectively	`AccountsReceivableNetCurrent`	$207.45M	USD	Point-in-time
Undesignated capital stock, shares outstanding (in shares)	`UndesignatedCapitalStockSharesOutstanding`	0.00	shares	Point-in-time
Inventories	`InventoryNet`	$171.64M	USD	Point-in-time
Inventories	`InventoryNet`	$180.84M	USD	Point-in-time
Undesignated capital stock, shares outstanding (in shares)	`UndesignatedCapitalStockSharesOutstanding`	0.00	shares	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Current assets held-for-sale	`AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$26.65M	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.01	USD	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	400.00M	shares	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	400.00M	shares	Point-in-time
Other current assets	`OtherAssetsCurrent`	$27.07M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$40.05M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$590.64M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$621.48M	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	157.14M	shares	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	157.64M	shares	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	157.64M	shares	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	157.14M	shares	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$226.20M	USD	Point-in-time
Property and equipment, net	`PropertyPlantAndEquipmentNet`	$234.20M	USD	Point-in-time
Right of use assets	`OperatingLeaseRightOfUseAsset`	$98.33M	USD	Point-in-time
Right of use assets	`OperatingLeaseRightOfUseAsset`	$100.86M	USD	Point-in-time
Goodwill	`Goodwill`	$872.74M	USD	Point-in-time
Goodwill	`Goodwill`	$980.08M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$550.61M	USD	Point-in-time
Intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$534.64M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$285.30M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$274.36M	USD	Point-in-time
Total assets	`Assets`	$2.64B	USD	Point-in-time
Total assets	`Assets`	$2.73B	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$31.51M	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$25.68M	USD	Point-in-time
Salaries, wages and related accruals	`EmployeeRelatedLiabilitiesCurrent`	$36.75M	USD	Point-in-time
Salaries, wages and related accruals	`EmployeeRelatedLiabilitiesCurrent`	$32.99M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$17.16M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$14.88M	USD	Point-in-time
Contract liabilities	`ContractWithCustomerLiabilityCurrent`	$28.43M	USD	Point-in-time
Contract liabilities	`ContractWithCustomerLiabilityCurrent`	$23.07M	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$12.02M	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$6.65M	USD	Point-in-time
Operating lease liabilities - current	`OperatingLeaseLiabilityCurrent`	$12.67M	USD	Point-in-time
Operating lease liabilities - current	`OperatingLeaseLiabilityCurrent`	$11.20M	USD	Point-in-time
Contingent consideration payable	`BusinessCombinationContingentConsiderationLiabilityCurrent`	$3.50M	USD	Point-in-time
Current liabilities held-for-sale	`LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent`	$1.59M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$1.41M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$4.22M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$128.51M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$135.23M	USD	Point-in-time
Deferred income taxes	`DeferredIncomeTaxLiabilitiesNet`	$71.58M	USD	Point-in-time
Deferred income taxes	`DeferredIncomeTaxLiabilitiesNet`	$88.98M	USD	Point-in-time
Long-term debt obligations	`LongTermDebtAndCapitalLeaseObligations`	$447.00M	USD	Point-in-time
Long-term debt obligations	`LongTermDebtAndCapitalLeaseObligations`	$350.00M	USD	Point-in-time
Operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$93.77M	USD	Point-in-time
Operating lease liabilities	`OperatingLeaseLiabilityNoncurrent`	$96.03M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$10.92M	USD	Point-in-time
Other long-term liabilities	`OtherLiabilitiesNoncurrent`	$17.36M	USD	Point-in-time
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding	`UndesignatedCapitalStockValue`	-	USD	Point-in-time
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding	`UndesignatedCapitalStockValue`	-	USD	Point-in-time
Common stock, par value $.01 per share; authorized 400,000,000; issued and outstanding 157,142,004 and 157,641,914 respectively	`CommonStockValue`	$1.58M	USD	Point-in-time
Common stock, par value $.01 per share; authorized 400,000,000; issued and outstanding 157,142,004 and 157,641,914 respectively	`CommonStockValue`	$1.57M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$764.27M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$721.54M	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$1.31B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$1.26B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-66.06M	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-63.66M	USD	Point-in-time
Total Bio-Techne's shareholders' equity	`StockholdersEquity`	$1.97B	USD	Point-in-time
Total Bio-Techne's shareholders' equity	`StockholdersEquity`	$1.96B	USD	Point-in-time
Total liabilities and shareholders' equity	`LiabilitiesAndStockholdersEquity`	$2.64B	USD	Point-in-time
Total liabilities and shareholders' equity	`LiabilitiesAndStockholdersEquity`	$2.73B	USD	Point-in-time

Income Statement 90 line items

Line Item	Tag	Value	Unit	Period
Net sales	`RevenueFromContractWithCustomerExcludingAssessedTax`	$541.24M	USD	2 Qtrs
Net sales	`RevenueFromContractWithCustomerExcludingAssessedTax`	$271.58M	USD	1 Quarter
Net sales	`RevenueFromContractWithCustomerExcludingAssessedTax`	$549.53M	USD	2 Qtrs
Net sales	`RevenueFromContractWithCustomerExcludingAssessedTax`	$272.60M	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$88.22M	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$187.75M	USD	2 Qtrs
Cost of sales	`CostOfGoodsAndServicesSold`	$96.01M	USD	1 Quarter
Cost of sales	`CostOfGoodsAndServicesSold`	$178.28M	USD	2 Qtrs
Gross margin	`GrossProfit`	$176.59M	USD	1 Quarter
Gross margin	`GrossProfit`	$183.36M	USD	1 Quarter
Gross margin	`GrossProfit`	$361.78M	USD	2 Qtrs
Gross margin	`GrossProfit`	$362.96M	USD	2 Qtrs
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$115.67M	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$221.00M	USD	2 Qtrs
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$93.01M	USD	1 Quarter
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$192.39M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$22.46M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$46.36M	USD	2 Qtrs
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$22.92M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$46.91M	USD	2 Qtrs
Total operating expenses	`OperatingExpenses`	$115.47M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$138.58M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$238.75M	USD	2 Qtrs
Total operating expenses	`OperatingExpenses`	$267.91M	USD	2 Qtrs
Operating income	`OperatingIncomeLoss`	$93.87M	USD	2 Qtrs
Operating income	`OperatingIncomeLoss`	$67.89M	USD	1 Quarter
Operating income	`OperatingIncomeLoss`	$124.21M	USD	2 Qtrs
Operating income	`OperatingIncomeLoss`	$38.00M	USD	1 Quarter
Other income (expense)	`NonoperatingIncomeExpense`	$-10.92M	USD	2 Qtrs
Other income (expense)	`NonoperatingIncomeExpense`	$-1.46M	USD	1 Quarter
Other income (expense)	`NonoperatingIncomeExpense`	$-4.62M	USD	1 Quarter
Other income (expense)	`NonoperatingIncomeExpense`	$45.94M	USD	2 Qtrs
Earnings before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$33.39M	USD	1 Quarter
Earnings before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$82.94M	USD	2 Qtrs
Earnings before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$66.43M	USD	1 Quarter
Earnings before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$170.15M	USD	2 Qtrs
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$30.41M	USD	2 Qtrs
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$16.42M	USD	1 Quarter
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$5.92M	USD	1 Quarter
Income taxes (benefit)	`IncomeTaxExpenseBenefit`	$4.49M	USD	2 Qtrs
Net earnings, including noncontrolling interest	`ProfitLoss`	$139.74M	USD	2 Qtrs
Net earnings, including noncontrolling interest	`ProfitLoss`	$78.46M	USD	2 Qtrs
Net earnings, including noncontrolling interest	`ProfitLoss`	$89.73M	USD	1 Quarter
Net earnings, including noncontrolling interest	`ProfitLoss`	$50.99M	USD	1 Quarter
Net earnings, including noncontrolling interest	`ProfitLoss`	$27.46M	USD	1 Quarter
Net earnings, including noncontrolling interest	`ProfitLoss`	$50.01M	USD	1 Quarter
Net earnings attributable to noncontrolling interest	`NetIncomeLossAttributableToNoncontrollingInterest`	$179.00K	USD	2 Qtrs
Net earnings attributable to Bio-Techne	`NetIncomeLoss`	$78.46M	USD	2 Qtrs
Net earnings attributable to Bio-Techne	`NetIncomeLoss`	$50.01M	USD	1 Quarter
Net earnings attributable to Bio-Techne	`NetIncomeLoss`	$139.56M	USD	2 Qtrs
Net earnings attributable to Bio-Techne	`NetIncomeLoss`	$27.46M	USD	1 Quarter
Foreign currency translation income (loss)	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$18.02M	USD	1 Quarter
Foreign currency translation income (loss)	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$6.42M	USD	2 Qtrs
Foreign currency translation income (loss)	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$17.37M	USD	1 Quarter
Foreign currency translation income (loss)	`OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent`	$-4.09M	USD	2 Qtrs
Foreign currency translation reclassified to earnings with Eminence deconsolidation	`OtherComprehensiveIncomeLossReleaseOfForeignCurrencyTransactionAndTranslationFromSalePortionAttributableToParent`	$119.00K	USD	2 Qtrs
Foreign currency translation reclassified to earnings with Eminence deconsolidation	`OtherComprehensiveIncomeLossReleaseOfForeignCurrencyTransactionAndTranslationFromSalePortionAttributableToParent`	$119.00K	USD	1 Quarter
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$-4.02M	USD	2 Qtrs
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$4.01M	USD	2 Qtrs
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$-3.67M	USD	1 Quarter
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent`	$-685.00K	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$14.36M	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$42.00K	USD	2 Qtrs
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$16.68M	USD	1 Quarter
Other comprehensive income (loss)	`OtherComprehensiveIncomeLossNetOfTax`	$2.40M	USD	2 Qtrs
Other comprehensive income (loss) attributable to noncontrolling interest	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest`	$-33.00K	USD	2 Qtrs
Other comprehensive income (loss) attributable to Bio-Techne	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$75.00K	USD	2 Qtrs
Other comprehensive income (loss) attributable to Bio-Techne	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$14.36M	USD	1 Quarter
Other comprehensive income (loss) attributable to Bio-Techne	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$16.68M	USD	1 Quarter
Other comprehensive income (loss) attributable to Bio-Techne	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$2.40M	USD	2 Qtrs
Comprehensive income attributable to Bio-Techne	`ComprehensiveIncomeNetOfTax`	$66.69M	USD	1 Quarter
Comprehensive income attributable to Bio-Techne	`ComprehensiveIncomeNetOfTax`	$139.63M	USD	2 Qtrs
Comprehensive income attributable to Bio-Techne	`ComprehensiveIncomeNetOfTax`	$41.82M	USD	1 Quarter
Comprehensive income attributable to Bio-Techne	`ComprehensiveIncomeNetOfTax`	$80.86M	USD	2 Qtrs
Basic (in dollars per share)	`EarningsPerShareBasic`	$0.32	USD	1 Quarter
Basic (in dollars per share)	`EarningsPerShareBasic`	$0.50	USD	2 Qtrs
Basic (in dollars per share)	`EarningsPerShareBasic`	$0.89	USD	2 Qtrs
Basic (in dollars per share)	`EarningsPerShareBasic`	$0.17	USD	1 Quarter
Diluted (in dollars per share)	`EarningsPerShareDiluted`	$0.17	USD	1 Quarter
Diluted (in dollars per share)	`EarningsPerShareDiluted`	$0.86	USD	2 Qtrs
Diluted (in dollars per share)	`EarningsPerShareDiluted`	$0.49	USD	2 Qtrs
Diluted (in dollars per share)	`EarningsPerShareDiluted`	$0.31	USD	1 Quarter
Basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	157.01M	shares	1 Quarter
Basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	157.83M	shares	2 Qtrs
Basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	157.53M	shares	1 Quarter
Basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	156.89M	shares	2 Qtrs
Diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	160.06M	shares	1 Quarter
Diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	161.77M	shares	2 Qtrs
Diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	161.75M	shares	1 Quarter
Diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	161.00M	shares	2 Qtrs

Cash Flow Statement 85 line items

Line Item	Tag	Value	Unit	Period
Net earnings, including noncontrolling interest	`ProfitLoss`	$139.74M	USD	2 Qtrs
Net earnings, including noncontrolling interest	`ProfitLoss`	$78.46M	USD	2 Qtrs
Net earnings, including noncontrolling interest	`ProfitLoss`	$89.73M	USD	1 Quarter
Net earnings, including noncontrolling interest	`ProfitLoss`	$50.99M	USD	1 Quarter
Net earnings, including noncontrolling interest	`ProfitLoss`	$27.46M	USD	1 Quarter
Net earnings, including noncontrolling interest	`ProfitLoss`	$50.01M	USD	1 Quarter
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$53.34M	USD	2 Qtrs
Depreciation and amortization	`DepreciationDepletionAndAmortization`	$56.34M	USD	2 Qtrs
Costs recognized on sale of acquired inventory	`FairValueWriteUpOfAcquiredInventory`	$364.00K	USD	2 Qtrs
Costs recognized on sale of acquired inventory	`FairValueWriteUpOfAcquiredInventory`	$400.00K	USD	2 Qtrs
Deferred income taxes	`DeferredIncomeTaxesAndTaxCredits`	$-6.37M	USD	2 Qtrs
Deferred income taxes	`DeferredIncomeTaxesAndTaxCredits`	$-22.31M	USD	2 Qtrs
Stock-based compensation expense	`ShareBasedCompensation`	$31.20M	USD	2 Qtrs
Stock-based compensation expense	`ShareBasedCompensation`	$22.85M	USD	2 Qtrs
Fair value adjustment to contingent consideration payable	`FairValueAdjustmentToContingentConsiderationPayable`	$-8.60M	USD	2 Qtrs
Fair value adjustment to contingent consideration payable	`FairValueAdjustmentToContingentConsiderationPayable`	$-3.50M	USD	2 Qtrs
Gain on sale of CCXI investment	`GainOnSaleOfInvestments`	$37.18M	USD	2 Qtrs
Fair value adjustment on available-for-sale investments	`FairValueAdjustmentOnAvailableForSaleSecurities`	$-283.00K	USD	2 Qtrs
Fair value adjustment on available-for-sale investments	`FairValueAdjustmentOnAvailableForSaleSecurities`	$-839.00K	USD	2 Qtrs
(Gain) loss on equity method investment	`EquityMethodInvestmentDividendsOrDistributions`	$4.29M	USD	2 Qtrs
Gain on sale of Eminence	`GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee`	-	USD	2 Qtrs
Gain on sale of Eminence	`GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee`	$11.68M	USD	2 Qtrs
Leases, net	`NoncashPortionOfLeaseExpense`	$640.00K	USD	2 Qtrs
Leases, net	`NoncashPortionOfLeaseExpense`	$1.20M	USD	2 Qtrs
Impairment of assets held-for-sale	`ImpairmentOfLongLivedAssetsToBeDisposedOf`	$6.04M	USD	2 Qtrs
Other operating activity	`OtherOperatingActivitiesCashFlowStatement`	$256.00K	USD	2 Qtrs
Other operating activity	`OtherOperatingActivitiesCashFlowStatement`	$112.00K	USD	2 Qtrs
Trade accounts and other receivables, net	`IncreaseDecreaseInAccountsAndOtherReceivables`	$-11.43M	USD	2 Qtrs
Trade accounts and other receivables, net	`IncreaseDecreaseInAccountsAndOtherReceivables`	$-20.33M	USD	2 Qtrs
Inventories	`IncreaseDecreaseInInventories`	$9.58M	USD	2 Qtrs
Inventories	`IncreaseDecreaseInInventories`	$18.36M	USD	2 Qtrs
Prepaid expenses	`IncreaseDecreaseInPrepaidExpense`	$2.00M	USD	2 Qtrs
Prepaid expenses	`IncreaseDecreaseInPrepaidExpense`	$3.15M	USD	2 Qtrs
Trade accounts payable, accrued expenses, contract liabilities, and other	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$5.38M	USD	2 Qtrs
Trade accounts payable, accrued expenses, contract liabilities, and other	`IncreaseDecreaseInAccountsPayableAndAccruedLiabilities`	$-11.54M	USD	2 Qtrs
Salaries, wages and related accruals	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$-4.30M	USD	2 Qtrs
Salaries, wages and related accruals	`IncreaseDecreaseInEmployeeRelatedLiabilities`	$-33.27M	USD	2 Qtrs
Income taxes payable	`IncreaseDecreaseInAccruedIncomeTaxesPayable`	$13.44M	USD	2 Qtrs
Income taxes payable	`IncreaseDecreaseInAccruedIncomeTaxesPayable`	$-9.88M	USD	2 Qtrs
Net cash provided by (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$120.47M	USD	2 Qtrs
Net cash provided by (used in) operating activities	`NetCashProvidedByUsedInOperatingActivities`	$142.50M	USD	2 Qtrs
Proceeds from sale of available-for-sale investments	`ProceedsFromSaleOfAvailableForSaleSecuritiesDebt`	$23.76M	USD	2 Qtrs
Proceeds from sale of available-for-sale investments	`ProceedsFromSaleOfAvailableForSaleSecuritiesDebt`	$26.51M	USD	2 Qtrs
Purchases of available-for-sale investments	`PaymentsToAcquireAvailableForSaleSecuritiesDebt`	$5.53M	USD	2 Qtrs
Purchases of available-for-sale investments	`PaymentsToAcquireAvailableForSaleSecuritiesDebt`	$20.50M	USD	2 Qtrs
Proceeds from sale of CCXI investment	`ProceedsFromSaleOfEquitySecuritiesFvNi`	$73.22M	USD	2 Qtrs
Additions to property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$15.66M	USD	2 Qtrs
Additions to property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$28.46M	USD	2 Qtrs
Acquisitions, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$101.18M	USD	2 Qtrs
Acquisitions, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$169.71M	USD	2 Qtrs
Distributions from (Investments in) Wilson Wolf	`ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital`	$2.15M	USD	2 Qtrs
Proceeds from sale of Eminence	`ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries`	$17.82M	USD	2 Qtrs
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-177.78M	USD	2 Qtrs
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-19.80M	USD	2 Qtrs
Cash dividends	`PaymentsOfDividendsCommonStock`	$25.21M	USD	2 Qtrs
Cash dividends	`PaymentsOfDividendsCommonStock`	$25.11M	USD	2 Qtrs
Proceeds from stock option exercises	`ProceedsFromStockOptionsExercised`	$16.98M	USD	2 Qtrs
Proceeds from stock option exercises	`ProceedsFromStockOptionsExercised`	$19.67M	USD	2 Qtrs
Re-purchases of common stock	`PaymentsForRepurchaseOfCommonStock`	$19.56M	USD	2 Qtrs
Re-purchases of common stock	`PaymentsForRepurchaseOfCommonStock`	$80.04M	USD	2 Qtrs
Borrowings under line-of-credit agreement	`ProceedsFromLongTermLinesOfCredit`	$449.66M	USD	2 Qtrs
Borrowings under line-of-credit agreement	`ProceedsFromLongTermLinesOfCredit`	$225.00M	USD	2 Qtrs
Repayments of long-term debt	`RepaymentsOfLinesOfCredit`	$128.00M	USD	2 Qtrs
Repayments of long-term debt	`RepaymentsOfLinesOfCredit`	$505.66M	USD	2 Qtrs
Taxes paid on RSUs and net share settlements	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$17.85M	USD	2 Qtrs
Taxes paid on RSUs and net share settlements	`PaymentsRelatedToTaxWithholdingForShareBasedCompensation`	$21.30M	USD	2 Qtrs
Other financing activity	`ProceedsFromPaymentsForOtherFinancingActivities`	$-2.46M	USD	2 Qtrs
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-104.00M	USD	2 Qtrs
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-9.89M	USD	2 Qtrs
Effect of exchange rate changes on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$-5.27M	USD	2 Qtrs
Effect of exchange rate changes on cash and cash equivalents	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$-4.55M	USD	2 Qtrs
Net change in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-7.88M	USD	2 Qtrs
Net change in cash and cash equivalents	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-50.44M	USD	2 Qtrs
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$164.68M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$172.57M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$180.57M	USD	Point-in-time
Cash and cash equivalents at beginning of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$130.13M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$164.68M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$172.57M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$180.57M	USD	Point-in-time
Cash and cash equivalents at end of period	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations`	$130.13M	USD	Point-in-time
Cash paid for income taxes	`IncomeTaxesPaid`	$37.65M	USD	2 Qtrs
Cash paid for income taxes	`IncomeTaxesPaid`	$26.41M	USD	2 Qtrs
Cash paid for interest	`InterestPaidNet`	$5.62M	USD	2 Qtrs
Cash paid for interest	`InterestPaidNet`	$8.59M	USD	2 Qtrs

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.